noted a new investment made by Sure Valley Ventures ("SVV") in the reality capture and volumetric video company, Volograms Limited (“Volograms”).
The investment firm confirmed its initial £1.1m investment into entrepreneur-led VC fund Sure Valley Ventures in late November 2019 in return for a 13% interest in SVV.
SVV has successfully led a new €1.5m investment round for Volograms, in which Atlantic Bridge University Fund and Enterprise Ireland have also made follow-on investments.
Pires highlighted that the funds raised by the investment round will accelerate Volograms' ambition to integrate AR capture technology into personal mobile devices.
A market leader in volumetric video, Volograms has worked with customers including Samsung, The London College of Fashion and The Royal College of Surgeons in Ireland.
Volograms' technology enables users to capture volumetric holograms of real people. By inserting holograms into videos, people can create their own immersive Augmented Reality ("AR") and Virtual Reality ("VR") content for use in apps, social media and VR headsets.
Shares in Pires Investments have rebounded strongly over the past three months from intraday lows of 1.55p to close on Tuesday at 3.1p.
The mobile AR market is forecast to grow from 1 bilion compatible devices and over US$8bn in revenue in 2019 to 2.5 billion compatible devices and $60bn in revenue by 2024.
Pires said growth potential for Volograms is therefore ‘significant’ and could attract success similar to other innovative products designed for mobile applications such as Pokémon Go.
“With the mobile AR market forecast for considerable growth in the coming years, we believe that Volograms is opening a new market category for AR photos and video,” said Peter Redmond, Chairman of Pires.
He added, “Already a market leader in volumetric videos and with a well-recognised customer base, we also believe that Volograms' technology will usher in the rapid expansion of the mobile AR industry and so this SVV investment in Volograms is exciting and well-timed.”
Follow News & Updates from Pires Investments here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Majid Shafiq, CEO of i3 Energy (AIM:I3E), and CFO, Graham Heath, discuss today’s follow-on deal to sell the Gain assets to Harvard Resources which will occur following the completion of the group’s previously announced C$80 million reverse takeover .
i3 Energy plc, an independent oil and gas company with assets and operations in the UK, Final Results for the year ended 31 December 2019 show significant operational progress for the pre-revenue company with net loss of £10.8m. To fund the Gain acquisition announced post period end in 2020, i3 is proposing to raise £30 million at a price of 5 pence per share, an 18% discount to the closing mid-price at which i3's shares suspended on 23 June 2020.
Oilex, the Operator of the PSC and on behalf of the JDPA joint venture, has reached amicable settlement with JPDA in East Timor with a settlement of US$0.8m payable in 2021 and 2022 financial years. The settlement amount is fully provided for in the FY19 accounts.
Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing in conjunction with Cytiva.
Shield Therapeutics said a reanalysis of the AEGIS-H2H study for its iron deficiency lead product Feraccru®/Accrufer® has confirmed the product as a credible alternative to IV therapy for patients with iron deficiency anaemia.